Wiznitzer, Max M.D

Wiznitzer, Max M.D., a solo pediatric neurologist operating as a sole proprietorship from Cleveland, Ohio, provides medical expert witness services and vaccine injury case review services to federal agencies exclusively as a prime contractor under small-business set-asides and full-and-open procurements. The vendor's entire footprint (100% prime, no subcontract work) concentrates on two concrete service lines: expert witness testimony and litigation support in pediatric neurology for the Department of Justice, and specialized medical case review and expert opinions supporting the Vaccine Injury Compensation Program and Countermeasures Injury Compensation Program administered by the Department of Health and Human Services Health Resources and Services Administration.

Customer concentration is extremely narrow. The top three agencies account for 90% of award count and 100% of combined potential value, dominated by HHS HRSA with 174 awards valued at $19.3 million in combined potential value. The Department of Justice Civil Division and U.S. Attorney's Offices together represent 8 awards worth approximately $86 thousand. This concentration reflects the vendor's specialized niche: the VICP/CICP case-review business anchors the portfolio, with DOJ litigation support as a secondary line of work.

Wiznitzer holds multiple Blanket Purchase Agreements with HHS HRSA, the largest being a recently established single-award BPA (HHSH250201200009B) with a $7.5 million ceiling running through June 2031, awarded June 26, 2026. This new BPA supersedes or complements older agreements (HHSH234200851007B with 85 task orders, HHSH250201400080B with 41 task orders, and HHSH250201200009B with 33 task orders) and establishes tiered hourly rates of $375 per hour for medical expert witnesses (MD/DO), $175 per hour for case reviewers with MD/DO degrees, and $125 per hour for case reviewers with PhD or advanced degrees. Individual task orders range from $125 to $100,000. DOJ maintains separate purchase order relationships with no parent vehicle structure. Recent representative work includes a $7,500 VICP case-review BPA call (March 2026), a $14,991 litigation-support purchase order from DOJ Civil Division (November 2025), and a $4,500 VICP case-review BPA call (April 2025).

Activity has declined substantially from 2022 (7 awards) to 2026 year-to-date (2 awards), though the June 2026 establishment of the $7.5 million HRSA BPA represents a major vehicle refresh. Only two awards with ultimate completion dates in the next twenty-four months carry combined potential value of $35 thousand, indicating minimal recompete exposure in the immediate term but significant reliance on the newly established HRSA BPA for future task order volume. Combined dollars obligated to date total $696 thousand (4% of combined potential value), reflecting the vendor's position as a on-call, as-needed resource rather than an active delivery engine.